Targeted photolysis of melanoma cells by Alfa-Terthienyl derivative labeled antimelanoma monoclonal antibody

Gabrio Roncucci; A. Di Stefano; P. Soldani; P. Neri; D. Neri

doi:10.1117/12.230949

31 January 1996 Targeted photolysis of melanoma cells by Alfa-Terthienyl derivative labeled antimelanoma monoclonal antibody

Gabrio Roncucci, A. Di Stefano, P. Soldani, P. Neri, D. Neri

Author Affiliations +

Proceedings Volume 2625, Photochemotherapy: Photodynamic Therapy and Other Modalities; (1996) https://doi.org/10.1117/12.230949
Event: BiOS Europe '95, 1995, Barcelona, Spain

Abstract

Antibody targeted chemotherapy is a relatively new technique which involves the specifically carrier mediated delivery ofchemotherapeutic agents to tumors or other pathogens for the treatment of such deseases. Conjugation of antibodies with photosensitizers (PSs) can also lead to potential therapeutic agents which combine photodynaniic cytotoxicity with specific antibody binding. The antibody mediated delivery of a photosensitizer molecule and the target destruction upon irradiation by light followed by production of singlet oxigen or other radicals, results in a higher therapeutic ratio compared to the conventional photodynarnic therapy (PDT). In this study the naturally occurring PS Alphà-Terthienile (ATT) was chemically derivatized with an amino group specific reactive side arm and in order to exploit its toxicity as an effector function suitable for targeted photolysis, covalently conjugated to the 225.28S monoclonal antibody (inAb) specific for the high molecular weight melanoma associated antigen (HMW-MAA). The 225-28S-ATT conjugate prepared was then tested against the melanoma cell line Co1o38 in comparison with HT29 tumor cells, not recognized by 225-28S mAb, as negative control. The selective uptake of labelled niAb 22528S-ATF and the melanoma cells death following irradiation can be observed. In conclusion the 225-28S-ATT conjugate, as far as one can judge from the effect on cells grown in vitro, seems a good candidate as a model to test the antibody targeted photolysis of melanoma cells for developing specific antimelanoma therapeutic agents.

Citation Download Citation

Gabrio Roncucci, A. Di Stefano, P. Soldani, P. Neri, and D. Neri "Targeted photolysis of melanoma cells by Alfa-Terthienyl derivative labeled antimelanoma monoclonal antibody", Proc. SPIE 2625, Photochemotherapy: Photodynamic Therapy and Other Modalities, (31 January 1996); https://doi.org/10.1117/12.230949

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available

Members: $17.00

Non-members: $21.00 ADD TO CART

PROCEEDINGS
11 PAGES

DOWNLOAD PAPER SAVE TO MY LIBRARY

GET CITATION

RIGHTS & PERMISSIONS

Get copyright permission Get copyright permission on Copyright Marketplace

KEYWORDS

Melanoma

Monoclonal antibodies

Photolysis

Photodynamic therapy

Proteins

Molecules

Signal detection

Show All Keywords

Keywords/Phrases

Search In:

Publication Years